Homogeneous expansion of human T-Regulatory cells via tumor necrosis factor receptor 2

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Okubo, Yoshiaki ^a   Mera, Toshiyuki ^a   Wang, Limei ^a   Faustman, Denise L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; TNFRSF1B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84889562494     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03153     Document Type: Article

References (49)

1. Liyanage, U. K. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immuno 169, 2756-2761 (2002) (Pubitemid 34921025)
2. Ormandy, L. A. et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65, 2457-2464 (2005)
3. Ichihara, F. et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9, 4404-4408 (2003) (Pubitemid 37248397)
4. Ochs, H. D., Gambineri, E. & Torgerson, T. R. IPEX, FOXP3 and regulatory Tcells: A model for autoimmunity. Immuno Res 38, 112-121 (2007) (Pubitemid 47574902)
5. Brunkow,M. E. et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nature Genetics 27, 68-73 (2001)
6. McMurchy, A. N., Bushell, A., Levings, M. K. &Wood, K. J. Moving to tolerance: Clinical application of T regulatory cells. Seminars in Immuno 23, 304-313 (2011)
7. Sehrawat, S. & Rouse, B. T. Tregs and infections: On the potential value of modifying their function. J Leukocyte Biol 90, 1079-1087 (2011)
8. Miyara, M. et al. Human FoxP31 regulatory T cells in systemic autoimmune diseases. Autoimmunity Rev 10, 744-755 (2011)
9. Teng, M. W., Ritchie, D. S., Neeson, P. & Smyth, M. J. Biology and clinical observations of regulatory T cells in cancer immunology. Current Topics in Micro and Immuno 344, 61-95 (2011)
10. Baranyi, U., Gattringer, M., Valenta, R. & Wekerle, T. Cell-based therapy in allergy. Current topics in Micro and Immuno 352, 161-179 (2011)
11. Taylor, P. A., Lees, C. J. & Blazar, B. R. The infusion of ex vivo activated and expanded CD4(1)CD25(1) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99, 3493-3499 (2002) (Pubitemid 34534513)
12. Wang, X. H., Lu, L. & Jiang, S. P. Regulatory T Cells: Customizing for the Clinic. Science Translational Med 3 (2011)
13. Brunstein, C. G. et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117, 1061-1070 (2011)
14. Tresoldi, E. et al. Stability of human rapamycin-expanded CD41CD251 T regulatory cells. Haematologica 96, 1357-1365 (2011)
15. Nadig, S. N. et al. In vivo prevention of transplant arteriosclerosis by ex vivoexpanded human regulatory T cells. Nat Med 16, 809-813 (2010)
16. Battaglia, M., Stabilini, A. & Tresoldi, E. Expanding human T regulatory cells with the mTOR-inhibitor rapamycin. Methods Mol Biol 821, 279-293 (2012)
17. Pahwa, R. et al. Isolation and expansion of human natural T regulatory cells for cellular therapy. Journal of Immuno. Methods 363, 67-79 (2010)
18. Hoffmann, P., Eder, R., Kunz-Schughart, L. A., Andreesen, R. & Edinger, M. Large-scale in vitro expansion of polyclonal human CD4(1)CD25high regulatory T cells. Blood 104, 895-903 (2004) (Pubitemid 38970590)
19. Lin, C. H. &Hunig, T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immuno 33, 626-638 (2003) (Pubitemid 36367666)
20. Lan, Q. et al. Induced Foxp3(1) regulatory T cells: A potential new weapon to treat autoimmune and inflammatory diseases J Mol Cell Biology 4, 22-28 (2012)
21. Sagoo, P. et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Science Translational Med 83, 1-10 (2011)
22. Edinger, M. & Hoffmann, P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Current Opinion Immuno. 23, 679-684 (2011)
23. Trzonkowski, P. et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD41CD251CD127-T regulatory cells. Clinical Immuno 133, 22-26 (2009)
24. Di Ianni, M. et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117, 3921-3928 (2011)
25. Hippen, K. L. et al.Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med 3, 83ra41 (2011)
26. Kim, Y. C. et al. Oligodeoxynucleotides stabilize Helios-expressing Foxp31 human T regulatory cells during in vitro expansion. Blood 119, 2810-2818 (2012)
27. Bacchetta, R. et al. Interleukin-10 Anergized Donor T Cell Infusion Improves Immune Reconstitution without Severe Graft-Versus-Host-Disease After Haploidentical Hematopoietic Stem Cell Transplantation. ASH Annual Meeting Abstracts 114, 45 (2009)
28. Desreumaux, P. et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology 143, 1207-1217 e1202 (2012)
29. Cardenas, P. A., Huang, Y. & Ildstad, S. T. The role of pDC, recipient T(reg) and donor T(reg) in HSC engraftment: Mechanisms of facilitation. Chimerism 2, 65-70 (2011)
30. Strauss, L. et al. Selective survival of naturally occurring human CD41CD251Foxp31 regulatory T cells cultured with rapamycin. J Immunol 178, 320-329 (2007) (Pubitemid 46033615)
31. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003) (Pubitemid 36222930)
32. Faustman, D. & Davis, M. TNF receptor 2 pathway: Drug target for autoimmune diseases. Nat Rev Drug Discov 9, 482-493 (2010)
33. Biton, J., Boissier, M. C.&Bessis, N. TNFalpha: Activator or inhibitor of regulatory T cells Joint, bone, spine: Reviews in Rheu 79, 119-123 (2012)
34. Petersen, C. M. et al. Bioactive human recombinant tumor necrosis factor-alpha: An unstable dimer Eur J Immuno 19, 1887-1894 (1989)
35. Carpentier, I., Coornaert, B. & Beyaert, R. Function and regulation of tumor necrosis factor type 2. Curr Med Chem 11, 2205-2212 (2004) (Pubitemid 38967740)
36. Welborn III, M. B. et al. A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. J Exp Med 184, 165-171 (1996)
37. Chen, X. et al. Co-expression of TNFR2 and CD25 identifies more of the functional CD4(1)FOXP3(1) regulatory T cells in human peripheral blood. European J Immuno 40, 1099-1106 (2010)
38. Annunziato, F. et al. Phenotype, localization, and mechanism of suppression of CD4(1)CD25(1) human thymocytes. J Exp Med 196, 379-387 (2002) (Pubitemid 34879113)
39. Chen, X., Baumel, M., Mannel, D. N., Howard, O. M. Z. & Oppenheim, J. J. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4(1)CD25(1) T regulatory cells. J Immuno 179, 154-161 (2007) (Pubitemid 46986529)
40. Ryu, S., Kodoma, S., Ryu, K., Schoenfeld, D. et al. Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. J Clin Invest 108, 63-72 (2001) (Pubitemid 32634923)
41. Rabinovitch, A., Suarez-Pinzon,W. L., Lapchak, P. H. et al. Tumor necrosis factor mediates the protection against autoimmune diabetes in BB rate. J Autoimmunity 8, 357-66 (1995)
42. Coenen, J. J. A., Koenen, H., van Rijssen, E., Hilbrands, L. B. & Joosten, I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27(1) subset of human CD4(1)CD25(1) regulatory T cells. Blood 107, 1018-1023 (2006) (Pubitemid 43156300)
43. Battaglia, M., Stabilini, A. & Roncarolo, M. G. Rapamycin selectively expands CD4(1)CD25(1)FoxP3(1) regulatory T cells. Blood 105, 4743-4748 (2005) (Pubitemid 40807298)
44. Abraham, R. T. & Wiederrecht, G. J. Immunopharmacology of rapamycin. Annual Review of Immuno 14, 483-510 (1996) (Pubitemid 26130192)
45. Faustman, D. L., Wang, L., Okubo, Y., Berger, D. et al. Proof-of-concept, randomized controlled clinical trial of BCG for treatment of long term type 1 diabetes. PLOSOne 7(8), e41756. doi:10.1371/journal.pone.0041756 (2013)
46. Mijnherr, G., Prrakken, B. J. & van Wijk, F. The effect of autoimmune arthritis treatment strategies on regulatroy T-cell dynamics. Current Opinion in Rheu 25, 260-267 (2013)
47. Chen, X. & Oppenheim, J. J. The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(1) FoxP3(1) regulatory T cells. Immuno 133, 426-433 (2011)
48. Sakaguchi, S. & Vignali, D. A. A. et al. The pasticity and stability of regulatory T cells. Nature Reviews Immun 13, 461-467 (2013)
49. Battaglia, M., Stabilini, A., Migliavacca, B., Horejs-Hoeck, J., Kaupper, T. & Roncarolo, M. G. Rapamycin promotes expansion of functional CD41CD251FOXP31 regulatory T cells in both healthy subjects and type 1 diabetic patients. Jounral of Immuno 177, 8338-8347 (2006) (Pubitemid 44893795)